Tag: ischemic heart disease (ihd) drugs market size

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Ischemic Heart Disease (IHD) Drugs Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The ischemic heart disease (IHD) drugs market size has demonstrated consistent expansion in recent years. This market is projected to increase from $6.36 billion in 2024 to $6.65 billion in 2025, achieving a compound annual growth rate (CAGR) of 4.5%. The expansion witnessed historically can be linked to factors such as the increasing worldwide prevalence of ischemic heart disease, enhanced awareness and diagnostic capabilities, evolving lifestyle and dietary patterns, government initiatives aimed at cardiovascular health, partnerships for clinical trials, and existing insurance coverage and reimbursement policies.

The ischemic heart disease (IHD) drugs market size is predicted to show steady expansion in the coming years. It is projected to increase to “$7.7 billion in 2029, achieving a compound annual growth rate (CAGR) of 3.7%.” This growth during the forecast period can be attributed to factors such as an aging demographic, personalized medicine strategies, a strong emphasis on cardiovascular disease prevention, global health policies and initiatives, and international research collaborations. Significant trends anticipated in this period include a shift towards precision medicine approaches, a focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, the integration of anti-inflammatory agents, and the development of antithrombotic and antiplatelet drugs.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp

Which Factors And Drivers Are Influencing The Ischemic Heart Disease (IHD) Drugs Market In 2025?

The expansion of the ischemic heart disease (IHD) drugs market is anticipated due to the increasing incidence of obesity and diabetes. Diabetes is a chronic metabolic condition marked by elevated blood glucose, while obesity is a medical state involving an excessive build-up of body fat, which can be detrimental to health. Individuals with obesity and diabetes frequently utilize ischemic heart disease drugs to address cardiovascular risk factors like high blood pressure and abnormal lipid levels, thereby lowering the probability of ischemic heart disease. For instance, a report from 2022 by the World Obesity Federation, a UK-based organization dedicated to combating obesity worldwide, projected that by 2030, one billion people globally, comprising 1 in 5 women and 1 in 7 men, will be living with obesity. Additionally, in June 2024, the UK’s National Health Service (NHS) disclosed that in 2023, they identified an additional 549,000 individuals in England at risk of type 2 diabetes. This increased the total number of people with pre-diabetes registered with a GP to 3,615,330, a substantial increase compared to 3,065,825 in 2022, marking a rise of nearly 20%. Consequently, the rising occurrence of obesity and diabetes is a key factor propelling the growth of the ischemic heart disease (IHD) drugs market.

What Are The Different Segment Classifications Within The Ischemic Heart Disease (IHD) Drugs Market?

The ischemic heart disease (ihd) drugs market covered in this report is segmented –

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents

2) By Disease Class: Angina Pectoris, Myocardial Infarction

3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors

2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers

4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril

5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan

6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine

7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

Which Ongoing Trends Are Expected To Shape The Ischemic Heart Disease (IHD) Drugs Market Outlook?

Companies engaged in the ischemic heart disease (IHD) drugs market are intensifying their efforts to develop cutting-edge myosin inhibitors, aiming to secure a competitive advantage. A cardiac myosin inhibitor is a pharmaceutical agent that diminishes myosin activity within the heart muscle, thereby decreasing contraction force. This approach is beneficial for conditions like hypertrophic cardiomyopathy (HCM), where excessive muscle thickening impairs cardiac function. For instance, in April 2022, Bristol Myers Squibb, a US-based pharmaceutical company, introduced Camzyos (mavacamten). This stands as the first cardiac myosin inhibitor approved for the treatment of adults with symptomatic new york heart association class ii-iii obstructive hypertrophic cardiomyopathy (HCM), intended to enhance functional capacity and alleviate symptoms. The medication operates as an allosteric and reversible inhibitor specifically targeting cardiac myosin, which leads to a reduction in hypercontractility and left ventricular hypertrophy, alongside an improvement in cardiac filling pressures. This mechanism helps to lessen dynamic left ventricular outflow tract (LVOT) obstruction.

Which Key Players Are Driving Competition In The Ischemic Heart Disease (IHD) Drugs Market?

Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

What Are The Key Regional Factors Influencing The Ischemic Heart Disease (IHD) Drugs Market Growth?

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Ischemic Heart Disease (IHD) Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13467&type=smp

Browse Through More Reports Similar to the Global Ischemic Heart Disease (IHD) Drugs Market 2025, By The Business Research Company

Antiparasitic Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antiparasitic-drugs-global-market-report

Congenital Diaphragmatic Hernia Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/congenital-diaphragmatic-hernia-drugs-global-market-report

Complicated Skin And Skin Structure Infections Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/complicated-skin-and-skin-structure-infections-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Ischemic Heart Disease (IHD) Drugs Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The ischemic heart disease (IHD) drugs market size has demonstrated consistent expansion in recent years. This market is projected to increase from $6.36 billion in 2024 to $6.65 billion in 2025, achieving a compound annual growth rate (CAGR) of 4.5%. The expansion witnessed historically can be linked to factors such as the increasing worldwide prevalence of ischemic heart disease, enhanced awareness and diagnostic capabilities, evolving lifestyle and dietary patterns, government initiatives aimed at cardiovascular health, partnerships for clinical trials, and existing insurance coverage and reimbursement policies.

The ischemic heart disease (IHD) drugs market size is predicted to show steady expansion in the coming years. It is projected to increase to “$7.7 billion in 2029, achieving a compound annual growth rate (CAGR) of 3.7%.” This growth during the forecast period can be attributed to factors such as an aging demographic, personalized medicine strategies, a strong emphasis on cardiovascular disease prevention, global health policies and initiatives, and international research collaborations. Significant trends anticipated in this period include a shift towards precision medicine approaches, a focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, the integration of anti-inflammatory agents, and the development of antithrombotic and antiplatelet drugs.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp

Which Factors And Drivers Are Influencing The Ischemic Heart Disease (IHD) Drugs Market In 2025?

The expansion of the ischemic heart disease (IHD) drugs market is anticipated due to the increasing incidence of obesity and diabetes. Diabetes is a chronic metabolic condition marked by elevated blood glucose, while obesity is a medical state involving an excessive build-up of body fat, which can be detrimental to health. Individuals with obesity and diabetes frequently utilize ischemic heart disease drugs to address cardiovascular risk factors like high blood pressure and abnormal lipid levels, thereby lowering the probability of ischemic heart disease. For instance, a report from 2022 by the World Obesity Federation, a UK-based organization dedicated to combating obesity worldwide, projected that by 2030, one billion people globally, comprising 1 in 5 women and 1 in 7 men, will be living with obesity. Additionally, in June 2024, the UK’s National Health Service (NHS) disclosed that in 2023, they identified an additional 549,000 individuals in England at risk of type 2 diabetes. This increased the total number of people with pre-diabetes registered with a GP to 3,615,330, a substantial increase compared to 3,065,825 in 2022, marking a rise of nearly 20%. Consequently, the rising occurrence of obesity and diabetes is a key factor propelling the growth of the ischemic heart disease (IHD) drugs market.

What Are The Different Segment Classifications Within The Ischemic Heart Disease (IHD) Drugs Market?

The ischemic heart disease (ihd) drugs market covered in this report is segmented –

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents

2) By Disease Class: Angina Pectoris, Myocardial Infarction

3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors

2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers

4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril

5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan

6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine

7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

Which Ongoing Trends Are Expected To Shape The Ischemic Heart Disease (IHD) Drugs Market Outlook?

Companies engaged in the ischemic heart disease (IHD) drugs market are intensifying their efforts to develop cutting-edge myosin inhibitors, aiming to secure a competitive advantage. A cardiac myosin inhibitor is a pharmaceutical agent that diminishes myosin activity within the heart muscle, thereby decreasing contraction force. This approach is beneficial for conditions like hypertrophic cardiomyopathy (HCM), where excessive muscle thickening impairs cardiac function. For instance, in April 2022, Bristol Myers Squibb, a US-based pharmaceutical company, introduced Camzyos (mavacamten). This stands as the first cardiac myosin inhibitor approved for the treatment of adults with symptomatic new york heart association class ii-iii obstructive hypertrophic cardiomyopathy (HCM), intended to enhance functional capacity and alleviate symptoms. The medication operates as an allosteric and reversible inhibitor specifically targeting cardiac myosin, which leads to a reduction in hypercontractility and left ventricular hypertrophy, alongside an improvement in cardiac filling pressures. This mechanism helps to lessen dynamic left ventricular outflow tract (LVOT) obstruction.

Which Key Players Are Driving Competition In The Ischemic Heart Disease (IHD) Drugs Market?

Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

What Are The Key Regional Factors Influencing The Ischemic Heart Disease (IHD) Drugs Market Growth?

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Ischemic Heart Disease (IHD) Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13467&type=smp

Browse Through More Reports Similar to the Global Ischemic Heart Disease (IHD) Drugs Market 2025, By The Business Research Company

Antiparasitic Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antiparasitic-drugs-global-market-report

Congenital Diaphragmatic Hernia Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/congenital-diaphragmatic-hernia-drugs-global-market-report

Complicated Skin And Skin Structure Infections Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/complicated-skin-and-skin-structure-infections-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Will The Ischemic Heart Disease (IHD) Drugs Market Valuation Change Between Now And 2029?

In recent times, the market size of drugs for ischemic heart disease (IHD) has been expanding steadily. The market, which stood at $6.36 billion in 2024, is expected to reach $6.65 billion by 2025, marking a compound annual growth rate (CAGR) of 4.5%. This growth during the historical period is a consequence of several factors such as a surge in worldwide cases of ischemic heart disease, enhancements in awareness and diagnostic measures, alterations in lifestyle and dietary habits, government protocol to boost cardiovascular health, partnerships for conducting clinical trials, and insurance coverage along with reimbursement policies.

The market for ischemic heart disease (IHD) medication is projected to experience consistent growth in the coming years, expected to reach “$7.7 billion by 2029 with a compound annual growth rate (CAGR) of 3.7%. This growth in the predicted period can be credited to factors such as the trends of an aging population, personalized medical practices, emphasis on cardiovascular prevention, as well as global health policies and initiatives, along with global research alliances. The projection period will likely witness a shift towards precision medicine practices, a heightened emphasis on novel anti-atherogenic agents, advancements in therapies that lower lipid levels, integration of anti-inflammatory medications, and the creation of antithrombotic and antiplatelet drugs.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp

Which Key Factors Are Fueling Growth In The Ischemic Heart Disease (IHD) Drugs Market?

The escalating rates of obesity and diabetes are anticipated to fuel the expansion of the ischemic heart disease (IHD) drugs market in the future. Diabetes, a chronic metabolic condition, results in elevated blood sugar levels, whereas obesity, marked by excessive body fat, can pose adverse effects on health. Drugs for ischemic heart disease are commonly prescribed to individuals with obesity and diabetes to manage cardiovascular risk elements like hypertension and dyslipidemia, thus reducing the risk of ischemic heart disease. For example, as per the World Obesity Federation’s data in 2022, a United Kingdom-based organization aimed at international efforts to cut down, avoid, and treat obesity, by 2030, one billion individuals worldwide, including one in every five women and one in every seven men, are projected to have obesity. According to the UK’s National Health Service in June 2024, the NHS detected an additional 549,000 individuals in England who could potentially develop type 2 diabetes in 2023. This brought the total count of people diagnosed with non-diabetic hyperglycemia, or prediabetes, and registered with a GP to 3,615,330. This is a considerable increase from 3,065,825 in 2022, showing almost a 20% hike. Therefore, the increasing rates of obesity and diabetes underpin the growth of the ischemic heart disease (IHD) drugs market.

What Are The Main Segment Classifications In The Ischemic Heart Disease (IHD) Drugs Market?

The ischemic heart disease (ihd) drugs market covered in this report is segmented –

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents

2) By Disease Class: Angina Pectoris, Myocardial Infarction

3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors

2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers

4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril

5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan

6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine

7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

How Are Industry Trends Steering The Expansion Of The Ischemic Heart Disease (IHD) Drugs Market?

Major firms in the ischemic heart disease (IHD) drugs market are concentrating on the creation of novel myosin inhibitors to strengthen their market position. A cardiac myosin inhibitor is a type of medication that reduces the activity of myosin in the heart muscle, thus reducing contraction stress. This is useful for conditions such as hypertrophic cardiomyopathy (HCM), a condition where excessive thickening of heart muscle affects its functioning. In April 2022, for example, Bristol Myers Squibb, a pharmaceutical company based in the US, introduced Camzyos (mavacamten). This is the first cardiac myosin inhibitor to be approved for treating adults with symptomatic New York Heart Association Class II-III obstructive hypertrophic cardiomyopathy (HCM), aimed to enhance functional capacity and alleviate symptoms. The medication acts as an allosteric and reversible inhibitor selective for cardiac myosin, reducing hypercontractility, left ventricular hypertrophy, and enhancing cardiac filling pressures. Consequently, this contributes to a decrease in dynamic left ventricular outflow tract (LVOT) obstruction.

Who Are The Major Stakeholders Operating In The Ischemic Heart Disease (IHD) Drugs Market?

Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

What Are The Emerging Regional Trends Driving The Ischemic Heart Disease (IHD) Drugs Market?

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13467&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Ischemic Heart Disease (IHD) Drugs Market Valued at Present and by 2029?

The market for drugs treating ischemic heart disease (IHD) has been demonstrating consistent growth over the past few years. The size of the market is projected to rise from $6.36 billion in 2024 to $6.65 billion in 2025, maintaining a compound annual growth rate (CAGR) of 4.5%. Several factors such as the increasing global incidence of ischemic heart disease, enhanced awareness and diagnostic methods, modifications in lifestyle and diet, governmental actions promoting cardiovascular health, partnerships for clinical trial testing, and insurance and reimbursement policies have played significant roles in the historical growth of this market.

In the next few years, the ischemic heart disease (IHD) drugs market is projected to experience consistent growth, reaching “$7.7 billion by 2029, with a compound annual growth rate (CAGR) of 3.7%“. This growth during the forecast period is linked to factors like the ageing population, personalized medicine methodologies, preventative cardiovascular measures, worldwide healthcare policies and initiatives, and international research partnerships. The period is also expected to witness trends such as a shift towards precision medicine methods, the introduction of innovative anti-atherogenic agents, advancements in lipid-lowering treatment, the inclusion of anti-inflammatory agents, and the creation of antithrombotic and antiplatelet drugs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp

#What Drivers Are Influencing Growth In The Ischemic Heart Disease (IHD) Drugs Market?

The surge in obesity and diabetes rates is predicted to stimulate the ischemic heart disease (IHD) drugs market’s expansion. Metabolic diseases such as diabetes, characterized by elevated blood sugar over a prolonged period, and obesity, defined by excessive body fat accumulation that impairs health, result in higher demand for ischemic heart disease drugs. These drugs help manage cardiovascular risk factors like hypertension and dyslipidemia, thus decreasing the probability of ischemic heart disease. The World Obesity Federation, a UK organization dedicated to combating obesity worldwide, projected in 2022 that by 2030, one billion people, including 1 in 5 women and 1 in 7 men, will be obese. Furthermore, according to the National Health Service, another UK government body, the NHS in 2023 identified an extra 549,000 individuals in England at risk of type 2 diabetes. Hence, the total number of people with non-diabetic hyperglycemia, also known as pre-diabetes, registered with a GP soared to 3,615,330 which is near about 20% rise compared to 3,065,825 in 2022. Therefore, the escalating prevalence of obesity and diabetes propels the growth of the ischemic heart disease (IHD) drugs market.

The ischemic heart disease (ihd) drugs market covered in this report is segmented –

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents

2) By Disease Class: Angina Pectoris, Myocardial Infarction

3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors

2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers

4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril

5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan

6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine

7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

What Trends Are Currently Influencing Growth In The Ischemic Heart Disease (IHD) Drugs Market?

Leading organizations in the Ischemic Heart Disease (IHD) drugs market are upping their game by focusing on the development of innovative myosin inhibitors to establish competitive dominance in the industry. These inhibitors are drugs designed to diminish myosin activity in cardiac muscles, thereby lessening force of contraction. They come particularly handy for conditions such as Hypertrophic Cardiomyopathy (HCM) where extreme muscle thickening compromises the functioning of the heart. For instance, in April 2022, US-based pharmaceutical major Bristol Myers Squibb introduced Camzyos (mavacamten), the inaugural cardiac myosin inhibitor given the nod for treatment of adult patients showing symptoms of New York Heart Association class II-III obstructive hypertrophic cardiomyopathy (HCM). This new drug aims to enhance functional capacity and symptoms, functioning as an allosteric and reversible inhibitor tailored for cardiac myosin. This reduces hypercontractility and left ventricular hypertrophy, and amplifies cardiac filling pressures, thereby aiding in the reduction of dynamic left ventricular outflow tract (LVOT) obstruction.

Which Companies Play A Key Role In The Development Of The Ischemic Heart Disease (IHD) Drugs Market?

Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC

https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

What Are The Key Regional Developments Shaping The Ischemic Heart Disease (IHD) Drugs Market?

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13467&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Ischemic Heart Disease (IHD) Drugs Market From 2025 To 2029?

In recent times, a consistent growth has been witnessed in the market size of drugs for Ischemic Heart Disease (IHD). The market, which is expected to escalate from $6.36 billion in 2024 to $6.65 billion in 2025, predicts an annual compound growth rate (CAGR) of 4.5%. Factors contributing to this growth during the historical period include an increased global incidence of ischemic heart disease, enhanced diagnostics and awareness, alterations in dietary habits and lifestyle, government-led cardiovascular health initiatives, partnerships for clinical trials, and insurance plus reimbursement policies.

In the coming years, the ischemic heart disease (IHD) drugs market is slated to experience stable expansion, inching towards a market value of $7.7 billion by 2029, signifying a compound annual growth rate (CAGR) of 3.7%. Factors such as the growing elderly population, individualized medication strategies, emphasis on preventative cardiovascular measures, worldwide health policies, and international research partnerships are believed to drive the growth during this forecast period. Additionally, the upcoming trends include a shift toward precision medication methodologies, a focus on groundbreaking anti-atherogenic agents, progress in lipid-reducing therapies, the incorporation of anti-inflammatory agents, and enhancement of antithrombotic and antiplatelet drugs.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp

What Are the Core Growth Drivers Propelling the Ischemic Heart Disease (IHD) Drugs Market Forward?

The rise in obesity and diabetes rates is projected to boost the expansion of the ischemic heart disease (IHD) drugs market. Diabetes, a chronic metabolic disorder that leads to elevated blood sugar levels, and obesity, a health condition characterized by extreme body fat accumulation that could harm health, are the key drivers. IHD medications are frequently employed in obese and diabetic patients to control cardiovascular risk factors such as hypertension and dyslipidemia, thereby reducing the risk of ischemic heart disease. For example, the World Obesity Federation, a UK-based organization leading global efforts to minimize, prevent, and manage obesity, reported in 2022, that by 2030, one billion individuals worldwide, including one in five women and one in seven men, will be obese. In another instance, the National Health Service, a UK government department, stated in June 2024, that in 2023, the NHS identified an additional 549,000 people in England at risk of developing type 2 diabetes, which increased the total number of people diagnosed with non-diabetic hyperglycemia or pre-diabetes, registered with a GP to 3,615,330. This is a substantial jump from 3,065,825 in 2022, reflecting a nearly 20% increase. Hence, the mounting occurrence of obesity and diabetes is stimulating the growth of the ischemic heart disease (IHD) drugs market.

What Segment Types Define the Ischemic Heart Disease (IHD) Drugs Market Structure?

The ischemic heart disease (ihd) drugs market covered in this report is segmented –

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents

2) By Disease Class: Angina Pectoris, Myocardial Infarction

3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors

2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers

4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril

5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan

6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine

7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13467&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Ischemic Heart Disease (IHD) Drugs Market?

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Emerging Trends that Are Influencing theIschemic Heart Disease (IHD) Drugs Industry Evolution?

Major firms in the ischemic heart disease (IHD) drug market are shifting their efforts towards inventing innovative myosin inhibitors to get a leg up on their competition. Cardiac myosin inhibitors are medications that suppress the activity of myosin in heart muscle, thus reducing the force of contraction. These inhibitors are advantageous for health issues like hypertrophic cardiomyopathy (HCM), where excessive muscle thickening negatively affects heart performance. Bristol Myers Squibb, a pharmaceutical entity based in the United States, rolled out Camzyos (mavacamten) in April 2022 as an example. It is the initial cardiac myosin inhibitor authorized for adult treatment with symptomatic New York Heart Association class II-III obstructive HCM to enhance functional capacity and symptoms. The medication operates as an allosteric and reversible inhibitor that specifically targets cardiac myosin. It reduces hypercontractility, left ventricular hypertrophy, and betters cardiac filling pressures, which subsequently minimizes dynamic left ventricular outflow tract (LVOT) obstruction.

View the full report here:

https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

What Is the Definition of the Ischemic Heart Disease (IHD) Drugs Market?

Ischemic heart disease (IHD) drugs are medications used to manage and treat a condition characterized by reduced blood flow to the heart muscle, often due to coronary artery narrowing. These drugs aim to alleviate symptoms, reduce the risk of complications such as heart attacks, and improve overall cardiac function.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13467

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the ischemic heart disease (ihd) drugs industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Projected Market Size and Growth Rates for the Ischemic Heart Disease (IHD) Drugs Market From 2025 To 2029?

The market size for ischemic heart disease (IHD) medications has robustly expanded in recent years. It is projected to increase from $6.36 billion in 2024 to $6.71 billion in 2025, with a compound annual growth rate (CAGR) of 5.6%. The prior growth can be associated with the escalating worldwide incidence of ischemic heart disease, enhanced consciousness and diagnostic measures, alterations in lifestyle and eating habits, government strategies for heart health, cooperative efforts for clinical studies, and insurance coverage along with reimbursement policies.

Predictions indicate consistent growth in the ischemic heart disease (IHD) drugs market in the upcoming years, expected to reach $7.86 billion in 2029 with a compound annual growth rate (CAGR) of 4.0%. Factors such as the aging population, personalized medicine strategies, emphasis on preventing cardiovascular diseases, worldwide health policies, and global research partnerships contribute to the growth expected during this period. Noteworthy trends for this forecast period involve a transition towards precision medicine, a focus on new anti-atherogenic agents, progress in lipid-lowering treatments, inclusion of anti-inflammatory agents, and the creation of antithrombotic and antiplatelet drugs.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Ischemic Heart Disease (IHD) Drugs Market?

The rise in obesity and diabetes is projected to boost the Ischemic Heart Disease (IHD) drug market’s growth. Diabetes, a long-term metabolic disorder that leads to increased blood glucose levels, and obesity, a condition where excess body fat accumulates, affecting health negatively, often necessitate the use of ischemic heart disease drugs. These drugs are utilized to control cardiovascular risk factors, such as hypertension and dyslipidemia, in individuals with obesity and diabetes, thus minimizing the chance of ischemic heart disease. For example, the World Obesity Federation predicted in 2022 that by 2030, a billion people worldwide—1 in every 5 women and 1 in every 7 men—will have obesity. In another example, the National Health Service reported in June 2024 that in 2023, they identified over half a million (549,000) extra at-risk individuals for developing type 2 diabetes in England. The total number of people registered with non-diabetic hyperglycemia, or pre-diabetes rose to 3,615,330, a significant surge from 3,065,825 in 2022, indicating an increase of nearly 20%. Consequently, the escalating prevalence of obesity and diabetes is contributing to the growth of the IHD drugs market. The surge in heart failure occurrences is expected to push the Ischemic Heart Disease (IHD) drugs market’s growth. Heart failure, a chronic disease where the heart muscle fails to supply enough blood to meet the body’s oxygen and blood needs, can lead to tiredness, difficulties in breathing, and challenges in conducting regular activities. IHD drugs have a crucial role in treating heart failure, mitigating ischemic heart disease risk factors and symptoms, and preventing heart failure altogether. These drugs inhibit the heart’s pacemaker activity and are useful in managing heart failure patients with reduced ejection fractions and high resting heart rates after a tolerated beta-blocker. For example, according to the Heart Failure Society of America in September 2023, over 6.7 million Americans aged 20 and above have heart failure, a figure expected to increase to 8.5 million Americans by 2030. Hence, the growing incidence of heart failure is accelerating the Ischemic Heart Disease (IHD) drug market’s expansion.

Which Key Market Segments Comprise the Ischemic Heart Disease (IHD) Drugs Market and Drive Its Revenue Growth?

The ischemic heart disease (IHD) drugs market covered in this report is segmented –

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents

2) By Disease Class: Angina Pectoris, Myocardial Infarction

3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors

2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers

4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril

5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan

6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine

7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13467&type=smp

Which Areas Are Leading Regions in the Ischemic Heart Disease (IHD) Drugs Market Expansion Across the Globe?

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in theIschemic Heart Disease (IHD) Drugs Market Over the Coming Years?

Leading businesses within the ischemic heart disease (IHD) drugs market are making strides in the development of innovative myosin inhibitors to secure their market position. Cardiac myosin inhibitors are designed to dampen the activity levels of myosin in the heart muscle, thereby reducing the force of contractions and bringing therapeutic benefits in situations like hypertrophic cardiomyopathy (HCM) where excess muscle thickness hampers heart function. Bristol Myers Squibb, a pharmaceutical firm based in the US, took an example of this initiative when they launched Camzyos (mavacamten) in April 2022. This is the debut cardiac myosin inhibitor designed to augment the functional capacity and symptom management for adults diagnosed with symptomatic New York heart association class II-III obstructive hypertrophic cardiomyopathy (HCM). The drug operates as a selective reversible inhibitor for cardiac myosin, effectively curbing hypercontractility, left ventricular hypertrophy, and bettering cardiac filling pressures. This, in effect, minimizes the dynamic left ventricular outflow tract (LVOT) obstruction.

View the full report here:

https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

How Is the Ischemic Heart Disease (IHD) Drugs Market Conceptually Defined?

Ischemic heart disease (IHD) drugs are medications used to manage and treat a condition characterized by reduced blood flow to the heart muscle, often due to coronary artery narrowing. These drugs aim to alleviate symptoms, reduce the risk of complications such as heart attacks, and improve overall cardiac function.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13467

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Ischemic Heart Disease (IHD) Drugs Market?

The surge in obesity and diabetes cases is anticipated to spur the expansion of the ischemic heart disease (IHD) drugs market. Diabetes, a chronic metabolic condition that results in elevated blood glucose levels, and obesity, a health condition marked by excessive body fat accumulation, adversely affecting wellbeing, frequently necessitate the use of ischemic heart disease medications. This is particularly so in managing cardiovascular risk factors such as hypertension and dyslipidemia, which subsequently abate the risk of ischemic heart disease. For example, the World Obesity Federation, a UK outfit spearheading global initiatives to curb, prevent and address obesity, forecasted that by 2030, one billion people all over the world, including one in five women and one in seven men, will be obese. Additionally, in June 2024, the UK’s National Health Service indicated that in 2023, an additional 549,000 individuals in England were identified as at risk of developing type 2 diabetes, which increased the total number of pre-diabetic individuals, registered with a GP, to 3,615,330, denoting a nearly 20% rise compared to 3,065,825 in 2022. Hence, the escalating prevalence of obesity and diabetes is fuelling the growth of the ischemic heart disease (IHD) drugs market.

Rising Instances of Heart Failure Catalyze Ischemic Heart Disease (IHD) Drugs Market Growth

 

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp

#What Growth Opportunities Will Drive the Ischemic Heart Disease (IHD) Drugs Market’s CAGR Through 2034?

The market size for drugs targeting ischemic heart disease (IHD) has experienced substantial growth recently. There is an expected growth from $6.36 billion in 2024 to $6.71 billion in 2025, showing a compound annual growth rate (CAGR) of 5.6%. Factors contributing to the growth observed in the past years include a worldwide increase in ischemic heart disease cases, enhanced consciousness and diagnostic procedures, lifestyle and dietary changes, government cardiovascular health programs, collaboration on clinical trials, and stipulations regarding insurance coverage and reimbursements.

Expectations are that the Ischemic Heart Disease (IHD) drugs market will experience consistent growth in the coming years, reaching a value of $7.86 billion by 2029. This represents a compound annual growth rate (CAGR) of 4.0%. Various factors contribute to this projected growth over the forecast period including demographic aging, personalization of medicine, a focus on cardiovascular prevention, international health policies and partnership initiatives, and global research collaborations. Key trends for this period are the transition to precision medicine, development of innovative anti-atherogenic agents, advancements in therapies lowering lipid levels, incorporation of anti-inflammatory agents, and the cultivation of antithrombotic and antiplatelet drugs.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13467

What Are the Key Market Innovations in theIschemic Heart Disease (IHD) Drugs Market Over the Coming Years?

Key players in the ischemic heart disease (IHD) drugs market are ramping up efforts to devise innovative myosin inhibitors to secure a leading position in the market. Cardiac myosin inhibitors are drugs that hinder myosin activity in cardiac muscles, thereby reducing contraction force. These inhibitors are particularly beneficial for heart conditions like hypertrophic cardiomyopathy (HCM) characterized by an abnormal thickening of the heart muscle, which hinders its functioning. To illustrate, Bristol Myers Squibb, a pharmaceutical company based in the US, launched Camzyos (mavacamten) in April 2022. This medication, the first of its kind designed for cardiac myosin inhibition, received approval for treating adults suffering from symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy (HCM), enhancing functional capacity and relieving symptoms. As an allosteric and reversible inhibitor exclusive to cardiac myosin, the drug diminishes hypercontractility and left ventricular hypertrophy while enhancing cardiac filling pressures. This, in turn, helps reduce dynamic left ventricular outflow tract (LVOT) obstruction.

Who Are the Top Companies Driving Innovation and Growth in theIschemic Heart Disease (IHD) Drugs Market?

Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

Which Key Market Segments Comprise the Ischemic Heart Disease (IHD) Drugs Market and Drive Its Revenue Growth?

The ischemic heart disease (IHD) drugs market covered in this report is segmented –

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents

2) By Disease Class: Angina Pectoris, Myocardial Infarction

3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors

2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers

4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril

5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan

6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine

7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=13467&type=smp

Which Regions Are Emerging as Leaders in the Ischemic Heart Disease (IHD) Drugs Market?

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Ischemic Heart Disease (IHD) Drugs Market 2025, By The Business Research Company:

Narcotic Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/narcotic-drugs-global-market-report

Preeclampsia Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report

Congenital Diaphragmatic Hernia Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/congenital-diaphragmatic-hernia-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the Ischemic Heart Disease (IHD) Drugs market right now?

In recent times, the market for ischemic heart disease (IHD) medications has seen significant growth. From $6.36 billion in 2024, it is projected to surge to $6.71 billion in 2025, with a compound annual growth rate (CAGR) of 5.6%. The expansion during the historic period stems from a rise in worldwide cases of ischemic heart disease, improved awareness and diagnostic measures, modifications in lifestyle and diet habits, governmental strategies for heart health, partnership for clinical trials, and policies for insurance coverage and reimbursement.

How fast Is the ischemic heart disease (ihd) drugs market expected to grow, and what’s its future value?

The market for drugs treating ischemic heart disease (IHD) is forecasted to experience consistent expansion in the coming years, positioning it at $7.86 billion in 2029 with an annual compound growth rate (CAGR) of 4.0%. Several factors are influencing this growth during the projection period such as the aging global population, the introduction of personalized medicine, increased stress on cardiovascular prevention, the implementation of worldwide health policies and initiatives, and partnerships in international research. Noteworthy trends during this prediction period will encompass a transition towards precision medicine methods, an enhanced focus on innovative anti-atherogenic agents, improvements in therapies lowering lipid levels, the inclusion of anti-inflammatory agents, and the invention of antithrombotic and antiplatelet drugs.

Get your ischemic heart disease (ihd) drugs market report here!

https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

What are the leading drivers of growth in the ischemic heart disease (ihd) drugs market?

Anticipated growth in the ischemic heart disease (IHD) drugs market is correlated to an increasing global prevalence of obesity and diabetes. These two health conditions, one responsible for dangerously excessive body fat and the other, a chronic metabolic disease causing high blood glucose levels, significantly impact the cardiovascular health. Consequently, IHD drugs have become a common method to manage associate risk factors like hypertension and dyslipidemia, thereby reducing the chance of ischemic heart disease. For example, the UK-based World Obesity Federation predicts that by 2030, one billion people worldwide will be obese, including a fifth of all women and a seventh of all men. Furthermore, in 2024, UK’s National Health Service reported that the number of individuals in England identified as at risk of developing type 2 diabetes has risen to more than half a million (549,000) in 2023. This brings the total of those with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330, representing an almost 20% increase from 3,065,825 in 2022. Therefore, the escalating rates of obesity and diabetes worldwide are contributing to the growth of the ischemic heart disease (IHD) drugs market. Rising cases of heart failure are another driving force for the growth of the ischemic heart disease (IHD) drug market. Heart failure, a chronic condition rendering the heart muscle unable to pump enough blood to meet the body’s oxygen and blood needs, often causes fatigue, shortness of breath, and difficulty performing everyday tasks. IHD drugs are instrumental in treating heart failure by lowering heart disease risk factors and symptoms and preventing the onset of heart failure. IHD drugs also hinder the heart’s pacemaker activity, providing benefits to heart failure patients with reduced ejection fractions and high resting heart rates, after a tolerated beta-blocker. An insight from the Heart Failure Society of America in September 2023 reveals that over 6.7 million Americans above 20 years old have heart failure (HF), and this figure is likely to reach 8.5 million by 2030. This suggests a growing link between increasing cases of heart failure and the growth of the ischemic heart disease (IHD) drug market.

What are the key segments defining the ischemic heart disease (ihd) drugs market?

The ischemic heart disease (IHD) drugs market covered in this report is segmented –

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents

2) By Disease Class: Angina Pectoris, Myocardial Infarction

3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors

2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers

4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril

5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan

6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine

7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp

Who are the key players steering the development of the ischemic heart disease (ihd) drugs market?

Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC

What emerging trends are influencing the growth of the ischemic heart disease (ihd) drugs market?

Key players in the ischemic heart disease (IHD) drugs market, such as Bristol Myers Squibb, are turning their attention towards the creation of novel myosin inhibitors as a means of enhancing their position in the market. These drugs work by curbing the activity of myosin in heart muscle, thereby reducing the force of contractions. This is particularly helpful in treating conditions such as hypertrophic cardiomyopathy (HCM), where the thickening of the heart muscle adversely affects its functionality. For instance, in April 2022, Bristol Myers Squibb introduced Camzyos (mavacamten), the first-ever approved cardiac myosin inhibitor designed for adults suffering from symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy (HCM). This medication enhances functional capacity and alleviates symptoms by acting as an allosteric and reversible inhibitor selective for cardiac myosin, decreasing hypercontractility and left ventricular hypertrophy and ameliorating cardiac filling pressures. These actions lead to a reduction in dynamic left ventricular outflow tract (LVOT) obstruction.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13467

Which regions are most influential in expanding the ischemic heart disease (ihd) drugs market?

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Narcotic Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/narcotic-drugs-global-market-report

Preeclampsia Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report

Congenital Diaphragmatic Hernia Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/congenital-diaphragmatic-hernia-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What are the Key Projections for the CAGR of the Ischemic Heart Disease (IHD) Drugs Market From 2025 to 2034?

The market for drugs treating ischemic heart disease (IHD) has experienced significant growth in recent times. The market which stands at $6.36 billion in 2024 is projected to reach $6.71 billion in 2025 with a compound annual growth rate (CAGR) of 5.6%. This past growth has occurred due to factors such as the increasing global incidents of ischemic heart disease, better awareness and diagnostics, changes in lifestyle and dietary habits, government policies supporting cardiovascular health, collaborations to conduct clinical trials, and insurance coverage and reimbursement policies.

The market size for drugs used in the treatment of ischemic heart disease (IHD) is predicted to experience constant growth in the upcoming years. It is forecasted to reach $7.86 billion in 2029, growing at a compound annual growth rate (CAGR) of 4.0%. The forecast period’s growth can be ascribed to factors such as the increasing age of the population, tailored medicine strategies, focus on cardiovascular prevention, worldwide healthcare policies and ventures, and global research partnerships. Key trends projected for this period incorporate a shift towards precision medicine methods, a concentrated effort on new anti-atherogenic agents, advancements in the domain of lipid-reducing therapies, the incorporation of anti-inflammatory agents, as well as the evolution of antithrombotic and antiplatelet drugs.

What Key Drivers Are Accelerating the Growth of the ischemic heart disease (ihd) drugs Market During the Forecast Period?

The Ischemic Heart Disease (IHD) drugs market is anticipated to grow due to the rising prevalence of obesity and diabetes worldwide. Diabetes, a sustained metabolic disorder, elevates blood glucose levels, while obesity engenders an excess buildup of body fat, which can cause various health issues. IHD drugs are commonly prescribed to obese and diabetic individuals to control cardiovascular risk factors including hypertension and dyslipidemia, reducing the likelihood of ischemic heart disease. For example, the UK-based World Obesity Federation reported in 2022 that by 2030, one billion people globally, encompassing 1 in 5 women and 1 in 7 men, will be obese. The National Health Service, another UK-based government department, announced in June 2024 that in 2023, over half a million (549,000) additional individuals were at risk of type 2 diabetes, elevating the total number of those with pre-diabetes registered with a GP to 3,615,330. This is a considerable rise compared to 3,065,825 in 2022, marking a nearly 20% increase. This growing prevalence of diabetes and obesity thus facilitates the expansion of the Ischemic Heart Disease drugs market. The projected surge in heart failure cases is another impelling factor for the growth of the Ischemic Heart Disease (IHD) drugs market. Heart failure, a persistent condition in which the heart cannot sufficiently pump blood to satisfy the body’s necessities for blood and oxygen, is the root cause of fatigue, breathing difficulty, and performance hindrance in daily activities. IHD drugs are pivotal in the treatment of heart failure, as they mitigate risk factors and symptoms, thus preventing heart failure. These medicaments curtail the heart’s pacemaker activity and greatly benefit heart failure patients with decreased ejection fractions and elevated resting heart rates after tolerating a beta-blocker. In September 2023, according to the US-based Heart Failure Society of America, an estimated 6.7 million Americans aged over 20 years had heart failure, and the number is set to ascend to 8.5 million Americans by 2030. Consequently, the increasing rate of heart failure contributes significantly to the growth of the Ischemic Heart Disease drug market.

Request Your Free Ischemic Heart Disease (IHD) Drugs Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp

What Are the Key Industry Players Leading the Charge in the Ischemic Heart Disease (IHD) Drugs Market’s Growth?

Major companies operating in the ischemic heart disease (ihd) drugs market report are:

• Pfizer Inc._x000D_

• F. Hoffmann-La Roche Ltd._x000D_

• Merck & Co. Inc._x000D_

• AbbVie Inc._x000D_

• Bayer AG_x000D_

How Are Market Trends and Shifts Impacting the Growth Trajectory of the Ischemic Heart Disease (IHD) Drugs Market?

Leading firms in the ischemic heart disease (IHD) drugs market, such as Bristol Myers Squibb, are striving to develop cutting-edge myosin inhibitors, aiming to secure a competitive advantage in the market. Myosin inhibitors are beneficial for conditions like hypertrophic cardiomyopathy (HCM) since these drugs lessen myosin activity in the heart muscle, thereby diminishing contraction force. These drugs are especially needed when the heart muscle becomes excessively thick and affects heart functioning. For instance, in April 2022, the US-based pharmaceutical company, Bristol Myers Squibb, introduced Camzyos (mavacamten). This new drug, the first of its kind as a cardiac myosin inhibitor, is authorized for the treatment of adults showing symptoms of new york heart association class ii-iii obstructive hypertrophic cardiomyopathy (HCM). Camzyos proves effective in enhancing functional capacity and symptoms by acting as an allosteric and reversible inhibitor selective for cardiac myosin. This action serves to mitigate hypercontractility and left ventricular hypertrophy while bettering cardiac filling pressures, helping to alleviate dynamic left ventricular outflow tract (LVOT) obstruction.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

Which Growth-Oriented Segments of the Ischemic Heart Disease (IHD) Drugs Market Are Leading the Industry’s Development?

The ischemic heart disease (IHD) drugs market covered in this report is segmented –

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents

2) By Disease Class: Angina Pectoris, Myocardial Infarction

3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors

2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers

4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril

5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan

6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine

7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

What Regions Are Influencing the Dynamics of the Ischemic Heart Disease (IHD) Drugs Market?

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Scope and Reach of the Ischemic Heart Disease (IHD) Drugs Market Defined?

Ischemic heart disease (IHD) drugs are medications used to manage and treat a condition characterized by reduced blood flow to the heart muscle, often due to coronary artery narrowing. These drugs aim to alleviate symptoms, reduce the risk of complications such as heart attacks, and improve overall cardiac function.

Browse Through More Similar Reports By The Business Research Company:

Narcotic Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/narcotic-drugs-global-market-report

Preeclampsia Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report

Congenital Diaphragmatic Hernia Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/congenital-diaphragmatic-hernia-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: